The features take much of the friction out of translating raw information into approachable slide decks and infographics. But is that really a good thing?
Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.
Deep Research pulled up sources I would never have discovered on my own, and while I'll comb through them in the upcoming ...
The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback